Mancini Anthony's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Mar 26, 2026
- Accession no.
- 0001610717-26-000137
- Filed
- Mar 26, 2026
- Trade date
- Mar 25, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.58M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mancini AnthonyCIK 0002124509 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | MOption exerciseAcquired | +37,450 | $33.62 | +$1,259,069 | 91,850 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −1,800 | $93.22F3 | −$167,796 | 90,050 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −3,128 | $94.16F4 | −$294,532.48 | 86,922 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −21,086 | $95.49F5 | −$2,013,502.14 | 65,836 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −11,036 | $96.43F6 | −$1,064,201.48 | 54,800 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −400 | $97.21F7 | −$38,884 | 54,400 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | MOption exerciseDisposed | −37,450 | $0.00 | $0 | 112,350 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $92.69 to $93.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $93.75 to $94.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $95.00 to $95.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $96.00 to $96.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $97.12 to $97.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Global Commercialization Officer